| Dr Jason T Lehr, DO | |
|
801 Broadway N, Fargo, ND 58102-3641 | |
| (701) 234-2000 | |
| Not Available |
| Full Name | Dr Jason T Lehr |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 11 Years |
| Location | 801 Broadway N, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558700435 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 14551 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Even at a hospital recognized for managing seriously ill patients, a systematic assessment of clinical measures associated with end-of-life care identified opportunities to improve treatment for those dying in the hospital, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.
A study led by a Loyola University Medical Center ENT physician provides a case study of a simple action that can reduce healthcare costs without compromising care.
A new modeling framework designed to track the transmission of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in the U.S. suggests that the coronavirus disease 2019 (COVID-19) epidemic was not under control by the end of May - just before containment measures were relaxed.
Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving a Food and Drug Administration-approved drug normally given for rheumatoid arthritis, according to an observational study at Cedars-Sinai.
› Verified 4 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Even at a hospital recognized for managing seriously ill patients, a systematic assessment of clinical measures associated with end-of-life care identified opportunities to improve treatment for those dying in the hospital, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.
A study led by a Loyola University Medical Center ENT physician provides a case study of a simple action that can reduce healthcare costs without compromising care.
A new modeling framework designed to track the transmission of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in the U.S. suggests that the coronavirus disease 2019 (COVID-19) epidemic was not under control by the end of May - just before containment measures were relaxed.
Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving a Food and Drug Administration-approved drug normally given for rheumatoid arthritis, according to an observational study at Cedars-Sinai.
› Verified 4 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Even at a hospital recognized for managing seriously ill patients, a systematic assessment of clinical measures associated with end-of-life care identified opportunities to improve treatment for those dying in the hospital, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.
A study led by a Loyola University Medical Center ENT physician provides a case study of a simple action that can reduce healthcare costs without compromising care.
A new modeling framework designed to track the transmission of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in the U.S. suggests that the coronavirus disease 2019 (COVID-19) epidemic was not under control by the end of May - just before containment measures were relaxed.
Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving a Food and Drug Administration-approved drug normally given for rheumatoid arthritis, according to an observational study at Cedars-Sinai.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason T Lehr, DO 801 Broadway N, Fargo, ND 58102-3641 Ph: (701) 234-2000 | Dr Jason T Lehr, DO 801 Broadway N, Fargo, ND 58102-3641 Ph: (701) 234-2000 |
News Archive
Even at a hospital recognized for managing seriously ill patients, a systematic assessment of clinical measures associated with end-of-life care identified opportunities to improve treatment for those dying in the hospital, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.
A study led by a Loyola University Medical Center ENT physician provides a case study of a simple action that can reduce healthcare costs without compromising care.
A new modeling framework designed to track the transmission of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in the U.S. suggests that the coronavirus disease 2019 (COVID-19) epidemic was not under control by the end of May - just before containment measures were relaxed.
Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving a Food and Drug Administration-approved drug normally given for rheumatoid arthritis, according to an observational study at Cedars-Sinai.
› Verified 4 days ago
Dr. Latif Sean Ougzin, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 Fax: 701-364-8078 | |
Manuel A. Colon-dejesus, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 701-234-5621 | |
John V Vinych, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 Fax: 701-364-8078 | |
Patrick J. Indergaard, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 701-234-6258 Fax: 701-234-7334 | |
Shelby Suzanne Best, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 | |
Layne Egan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5225 23rd Ave S, Fargo, ND 58104 Phone: 701-417-2575 | |
Alanna Velo, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 218-205-7365 |